Related Experiment Video
Updated: Jul 18, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Thrombus architecture is influenced by the antiplatelet loading treatment in patients with acute myocardial
Tobias Harm1, Dominik Rath1, Klaus-Peter Kreisselmeier1
1Department of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls University Tübingen, Otfried-Müller-Straße 10, 72076 Tübingen, Germany.
Insights
Prasugrel pre-treatment significantly altered thrombus composition in ST-segment elevation myocardial infarction patients undergoing PCI. This antiplatelet strategy reduced fibrin and inflammatory cells, impacting thrombo-inflammatory pathways.
Area of Science:
- Cardiology
- Thrombosis Research
- Pharmacology
Background:
- Intracoronary thrombus formation is a primary cause of acute myocardial infarction, driven by platelet activation.
- Current data lack insights into how pre-PCI antiplatelet strategies affect thrombus histology.
Purpose of the Study:
- To investigate the impact of pre-interventional P2Y12-inhibitors (clopidogrel and prasugrel) on intracoronary thrombus composition.
- To identify histological and molecular changes in thrombi associated with different antiplatelet pre-treatments.
Main Methods:
- Prospective enrollment of 104 ST-segment elevation myocardial infarction patients undergoing PCI and thrombus aspiration.
- Immunohistochemical staining and RNA-sequencing (Nanostring analysis) of aspirated thrombi.
- Comparison of thrombus characteristics between patients pre-treated with prasugrel or clopidogrel loading doses.
Main Results:
- Prasugrel pre-treatment significantly altered thrombus architecture compared to clopidogrel.
- Fibrin content was reduced (41.8% vs. 66.7%) and MPO-positive inflammatory cells decreased (90.5 vs. 201.1) with prasugrel.
- Significant differences in RNA expression and signaling pathways of thrombo-inflammatory processes were observed between treatment groups.
Conclusions:
- Pre-interventional antiplatelet therapy significantly impacts thrombus remodeling and composition.
- Prasugrel pre-treatment may lower the risk of recurrent cardiovascular events by altering thrombus architecture and inflammatory response.
Background:
Intracoronary thrombus formation is a main cause of acute myocardial infarction triggered by platelet activation. However, there are no data on the impact of different treatment strategies with antiplatelet agents before percutaneous coronary intervention (PCI) on histological characteristics of thrombus formation.
Objective:
In this study, we investigate the impact of preinterventional administration of the P2Y12-inhibitors clopidogrel and prasugrel on thrombus composition, highlighting significant changes associated with the antiplatelet pre-treatment.
Methods:
We prospectively enrolled 104 consecutive patients with ST-segment elevation myocardial infarction (STEMI) undergoing immediate PCI and thrombus aspiration by immunohistochemical staining along with RNA-sequencing employing Nanostring analysis. Fifty-two patients were treated with either prasugrel loading (60 mg) or clopidogrel loading (600 mg) prior to PCI, respectively.
Results:
In Patients with STEMI, intracoronary thrombus architecture was significantly altered between patients pre-treated with prasugrel when compared to clopidogrel. Fibrin content of thrombi was significantly decreased (41.8 % versus 66.7 %, p = 0.009) after pre-treatment with prasugrel compared to clopidogrel. Furthermore, levels of MPO positive cells in intracoronary thrombi were significantly decreased in patients with prasugrel pre-treatment (90.5 versus 201.1, p = 0.014) indicating an association of antiplatelet pre-treatment and the inflammatory responses during thrombus formation. Most strikingly, we observed significant differences among both pre-treatment groups regarding altered RNA expression and signaling pathways of thrombo-inflammatory processes within the thrombotic material, which were independently associated with antiplatelet strategies.
Conclusions:
Our study elucidates the impact of antiplatelet pre-treatment on thrombus remodeling and architecture, thereby lowering the risk of recurrent adverse cardiovascular events in prasugrel-treated patients.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:26Angina IV: Management